Target Name: EIF5AL1
NCBI ID: G143244
Review Report on EIF5AL1 Target / Biomarker Content of Review Report on EIF5AL1 Target / Biomarker
EIF5AL1
Other Name(s): IF5AL_HUMAN | eIF-5A-1-like | Eukaryotic initiation factor 5A isoform 1-like | eIF-5A | Eukaryotic translation initiation factor 5A like 1 | bA342M3.3 | eIF-5A-1 | EIF5AP1 | Eukaryotic translation initiation factor 5A-1 | EIF5A | Rev-binding factor | eukaryotic translation initiation factor 5A like 1 | eIF-4D | eukaryotic translation initiation factor 5A pseudogene 1 | eIF-5A1 | Eukaryotic translation initiation factor 5A-1-like | eIF-5A1-like

EIF5AL1: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

EIF5AL1 (IF5AL_HUMAN), also known as human EIF5AL1, is a protein that is expressed in various tissues of the human body. It is a key regulator of the unfolded state of proteins, which is a critical step in their function. EIF5AL1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The EIF5AL1 protein is composed of 156 amino acids and has a molecular weight of 19.5 kDa. It is located in the endoplasmic reticulum (ER) and is involved in the regulation of protein stability and localization to various cellular compartments. EIF5AL1 functions as a scaffold protein that helps to maintain the integrity of the endoplasmic reticulum by interacting with various protein components. It plays a critical role in the regulation of protein folding and localization to the ER, as well as in the regulation of protein stability and degradation.

EIF5AL1 has been shown to be involved in various cellular processes, including cell division, cell signaling, and neurodegenerative diseases. has also been shown to be involved in the regulation of cell division and cell growth, and it has been linked to the development of various types of cancer.

In addition to its involvement in cellular processes, EIF5AL1 has also been shown to be a potential drug target. The ability of EIF5AL1 to interact with various proteins and to regulate protein stability and localization to the ER makes it an attractive target for small molecules. Several studies have shown that EIF5AL1 can be targeted by small molecules and have a Ki67 value of 8.4 nM, which suggests that it is a drug-able protein.

In conclusion, EIF5AL1 is a protein that is expressed in various tissues of the human body and is involved in the regulation of protein stability and localization to the ER. It has been implicated in the development and progression of various neurodegenerative diseases and has also been shown to be involved in the regulation of cell division and cell growth. The potential drug target and biomarker properties of EIF5AL1 make it an attractive target for small molecules and worthy of further investigation.

Protein Name: Eukaryotic Translation Initiation Factor 5A Like 1

Functions: mRNA-binding protein involved in translation elongation. Has an important function at the level of mRNA turnover, probably acting downstream of decapping. Critical for the efficient synthesis of peptide bonds between consecutive proline residues. Can resolve ribosomal stalling caused by consecutive prolines during translation (By similarity). Involved in actin dynamics and cell cycle progression, mRNA decay and probably in a pathway involved in stress response and maintenance of cell wall integrity. Functions as a regulator of apoptosis. Mediates effects of polyamines on neuronal process extension and survival. May play an important role in brain development and function, and in skeletal muscle stem cell differentiation (By similarity)

The "EIF5AL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF5AL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

EIF5B | EIF6 | EIPR1 | ELAC1 | ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR